![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SEATTLE GENETICS RECEIVES U.S. PATENTS FOR SGN-40 PROGRAM
SEATTLE GENETICS RECEIVES U.S. PATENTS FOR SGN-40 PROGRAM
Seattle Genetics has announced that the U.S. Patent and Trademark Office has issued two patents relating to the company's SGN-40 program.
The patents claim composition of matter and methods of using anti-CD40 antibodies for the treatment of cancer. Seattle Genetics is currently conducting Phase I clinical trials of SGN-40, an anti-CD40 antibody, in multiple myeloma and non-Hodgkin's lymphoma. The company plans to initiate an additional Phase I study in chronic lymphocytic leukemia during the first half of 2005.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct